Equity Rollover in a Corporate Vet Practice Sale: What You're Actually Agreeing To

NVA offers you $4M for your practice — $3M cash at close and $1M in "platform equity." The pitch: when NVA sells again in 4 years, that equity could be worth $2.5M or more. The risk: it could be worth $0. This guide explains how to evaluate a rollover offer before you sign anything.

What Equity Rollover Means

In most corporate vet acquisitions, you don't just sell your practice and leave. The buyer wants you to stay involved — and they want some of your sale proceeds to stay invested in the platform alongside their money. This is equity rollover: instead of receiving 100% cash at close, you receive a portion of the purchase price as equity in the acquiring company (or its holding entity).

The rollover equity represents your continued ownership stake in a larger, growing veterinary platform. The thesis: after the PE firm's typical 3–7 year hold period, the platform is sold again — the "second bite" — at a higher valuation, and your equity is worth more than what you originally rolled over.

It sounds attractive. It often is. But the rollover is a different investment than the practice you built — with different liquidity, different risk, and a tax structure you need to understand before you agree to it.

Typical Deal Structures by Buyer Type

Smaller regional PE-backed platforms typically offer the most rollover equity — and the highest headline multiples — because they need sellers to share the risk of a platform still early in its growth story.

The Tax Treatment: IRC §721

When structured correctly, rolling equity into a partnership or LLC taxed as a partnership is a tax-deferred event under IRC §721. You don't pay capital gains tax on the rollover tranche at close. The gain is deferred until the future exit — the second bite.

The key requirement: the receiving entity must be a partnership or LLC taxed as a partnership. If the buyer's holding entity is a C-corporation, §721 does not apply and the rollover tranche is taxable at close. Verify the entity structure before signing.

A few nuances matter:

• Boot received at close: Any cash you receive at close is taxable. Only the rollover tranche is deferred. If you roll $1M of a $4M deal, the $3M cash portion is taxed normally.
• Hot assets (§751): Even in a §721 rollover, if the practice has ordinary income items (unrealized receivables, inventory), those may trigger partial ordinary income recognition. Your CPA needs to check this.
• Deferral is not forgiveness: The deferred gain follows you. You'll pay tax at exit — potentially at higher rates if tax law changes, and on a potentially larger gain if the platform appreciates.

If the buyer entity is a corporation and they offer §351 treatment instead, the same nonrecognition concept applies — but the corporate structure creates different downstream consequences (no partnership basis adjustments, double taxation risk on distributions). Get tax advice specific to the deal structure.

How to Value Your Rollover Equity

The number on the term sheet — say, $1M in rollover equity — is a notional value, not a liquid value. Here's why it's rarely worth face value on the day you sign:

Illiquidity discount

You cannot sell private equity. Until the platform's exit event, your rollover equity is locked up — often 3–7 years. Studies of private illiquidity discounts consistently find that a 20–35% discount is appropriate for minority interests in private companies with no redemption rights.¹ A $1M rollover at face value may be worth $650,000–$800,000 in economic terms on day one.

Minority interest position

You hold a small slice of a large platform. You have no control over business decisions, hiring, pricing, geographic expansion, or — critically — when the exit happens. Minority interest discounts typically add another 15–25% reduction from the control-value price.

Platform leverage

PE-backed platforms use significant debt to acquire their hospital portfolio. If the platform took on 4–6× EBITDA in acquisition debt, a period of poor performance (revenue decline, staffing crisis, regulatory change) can wipe out equity before debt holders. Your rollover equity sits at the bottom of the capital stack.

Preferred return waterfall

Many PE structures include a preferred return for the fund — commonly 8% per year, accrued on invested capital — before you see a dollar on exit. If the platform held for 5 years with an 8% preferred, the PE fund must first recoup its invested capital plus 40% before the rollover pool participates. On a modestly performing platform, this can dramatically cut the rollover's effective return.

The Second-Bite Math: When Rollover Actually Pays Off

For rollover equity to beat "just take the cash," the platform needs to:

1. Grow EBITDA substantially during the hold period (organic growth + acquisitions)
2. Sell at a higher multiple than it paid for your practice (platform premium vs. single-hospital price)
3. Exit within the timeline you can afford to wait
4. Return capital in a structure that clears the preferred waterfall before hitting your interest

The "platform premium" thesis is real: a PE platform with 30 hospitals and $15M EBITDA may sell at 14–16× EBITDA vs. the 8–10× they paid for individual hospitals. If you own 2% of that platform and the multiple expands, you benefit. But this requires the platform to succeed on multiple dimensions simultaneously.

A rough decision rule: if you believe the platform will at least double its EBITDA before exit and execute a clean sale at an equal or higher multiple, the rollover is likely worth taking. If you're uncertain about either condition, the cash today is usually the better choice — especially after applying the illiquidity discount.

Key Rollover Term Sheet Provisions

These are the provisions that determine whether your rollover equity is actually worth protecting:

Tag-along rights

If the PE fund sells its controlling stake, you have the right to sell your proportional interest on the same terms. Without tag-along rights, the majority owner can exit cleanly while you remain a minority holder in a platform you no longer control — and can't exit.

Drag-along rights

The PE fund can require you to sell your equity when they execute a platform sale. This is standard and generally in your interest — it ensures you're included in the exit event rather than left behind. Review the terms: drag-along should require the sale to be at least equal to what you would receive on a pro-rata basis.

Anti-dilution protection

If the platform raises additional equity at a lower valuation (a down round), anti-dilution provisions protect your equity from being disproportionately diluted. Broad-based weighted average anti-dilution is the most common and fairest form. Without it, an emergency capital raise could cut your economic interest significantly.

Information rights

You're entitled to periodic financial statements — typically annual audited financials and quarterly unaudited P&Ls. Without information rights written into the agreement, you may have no visibility into how the platform is performing until the exit event arrives.

ROFO (Right of First Offer)

Before selling your equity to a third party, you must first offer it to the company. This is standard. What matters is whether the ROFO applies on reasonable terms — the company should have to match a legitimate third-party offer, not simply block the sale with an artificially low counter.

Exit timing provisions

If the PE fund hasn't exited within a specified period (typically 7–10 years), do you have any put right — the ability to force a redemption of your equity at fair market value? Without a put right, you could be a minority holder with no exit for an indefinitely long period.

When to Take More Cash Instead

The rollover structure favors you when:

• The platform is early-stage, growing fast, and the second-bite upside is real
• The waterfall structure is seller-friendly (limited preferred, no participating preferred)
• You have strong tag-along/drag-along and information rights
• You trust the PE firm's track record with vet platforms specifically
• You have adequate liquid wealth outside the rollover to cover your retirement needs

Push for more cash (or decline rollover) when:

• The platform is highly leveraged and you're unclear on the capital structure
• The preferred return is substantial (12%+) or the waterfall is complex
• Tag-along rights are absent or conditional
• Your personal financial plan requires liquidity from this sale
• The deal doesn't include information rights or a reasonable put option
• You're already concentrated in vet industry risk (the same forces that hurt your practice will hurt the platform)

QSBS: Does It Apply?

Qualified Small Business Stock (IRC §1202) can exclude up to $10M (or 10× basis) of capital gain from federal tax if the company was a C-corp with gross assets under $50M at issuance and the stock is held more than 5 years. After OBBBA (2025), the QSBS exclusion increased to $15M for stock issued after July 2025.²

In most corporate vet deals, QSBS does not apply to rollover equity because:

• Most vet platforms use LLC/LP structures for their operating entities — LLCs don't qualify for §1202
• Large platforms (NVA, Mars) have gross assets far exceeding the $50M threshold
• The 5-year holding requirement must run from issuance — tight for a PE fund with a 4–5 year hold timeline

That said, if the rollover entity is a newly formed C-corp holding company with limited assets, ask your M&A attorney whether the rollover equity could qualify. It's rare but not impossible, and a $15M exclusion is worth investigating.

Case Example: $3.5M Practice, 25% Rollover

A single-DVM small-animal practice in the Midwest with $650K EBITDA receives a $3.5M offer from a PE-backed regional platform at 5.4× EBITDA. Deal structure: $2.625M cash at close (75%) and $875K in rollover equity (25% in the platform LLC).

Tax at close: On the $2.625M cash portion, assume $2.4M in gain (low basis). Federal tax: approximately $572K (20% LTCG + 3.8% NIIT on the gain above $200K threshold). Net cash at close: ~$2.05M. The $875K rollover deferred under §721 — no tax today.

Rollover math — optimistic case: The platform doubles EBITDA over 5 years and sells at 14× to a large national. The DVM holds 1.8% of the platform post-dilution. At a $140M exit, the DVM's equity is worth ~$2.5M before waterfall. After PE preferred return (8% × 5 years on $60M fund = $24M accrued), proceeds net to roughly $1.8M. That's a 2× return on $875K over 5 years — a solid 15% annualized IRR. Total after-tax sale proceeds: ~$3.85M.

Rollover math — conservative case: Platform growth is modest, exit multiple compresses, and the DVM nets $500K on the $875K rollover after waterfall. Total after-tax proceeds including the cash component: ~$2.55M — significantly less than the face value implied.

The same deal, two realistic scenarios, $1.3M gap. Which scenario depends on factors largely outside your control. That gap is what warrants careful analysis before signing.

Before You Agree to Rollover Equity

Three conversations to have before signing:

1. Tax advisor: Confirm the entity structure qualifies for §721, review hot assets that could trigger immediate recognition, model the cash-basis tax hit vs. rollover-deferred scenario.
2. M&A attorney: Review the rollover term sheet for waterfall structure, tag-along/drag-along completeness, anti-dilution terms, and put rights. A specialist who's reviewed vet platform deals is worth the fee.
3. Financial planner: Model whether your retirement plan works without the rollover proceeds. If it does, rollover is a speculative upside. If it doesn't, rollover adds risk to a plan that depends on that liquidity.